Ultragenyx Pharmaceutical Inc宣布,其针对成骨不全症开发的药物Setrusumab(研发代号Ux143)在三期临床试验Orbit与Cosmic中取得积极结果。这两项研究旨在评估该药物对患者骨骼强度与骨折风险的改善效果,初步数据表明其在主要终点上表现出显著疗效。公司计划基于现有结果与监管机构进一步沟通,推进后续申报流程。
Ultragenyx Pharmaceutical Inc宣布,其针对成骨不全症开发的药物Setrusumab(研发代号Ux143)在三期临床试验Orbit与Cosmic中取得积极结果。这两项研究旨在评估该药物对患者骨骼强度与骨折风险的改善效果,初步数据表明其在主要终点上表现出显著疗效。公司计划基于现有结果与监管机构进一步沟通,推进后续申报流程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.